ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

The treatment, now available in England, targets myeloma, a blood cancer affecting plasma cells in the bone marrow. It ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is ...

New research presented by Noella Collado-Gisbert reveals that tracking residual disease kinetics in multiple myeloma predicts ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why these results matter for amyloidosis -- and how innovations across plasma ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

Final results from the Phase II CONCEPT trial reveal that isatuximab combined with carfilzomib, lenalidomide, and ...